The effects of curcumin on respiratory problems due to mustard gas

Investigation of the effects of oral curcumin on pulmonary complications due to sulfur mustard exposure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013091114521N2

Enrollment

Registered

2013-12-10

Start date

2012-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic respiratory problems due to mustard gas intoxication. Chronic respiratory conditions due to chemicals, gases, fumes and vapours

Interventions

Intervention 1: Intervention group: curcumin (1500 mg/day). Intervention 2: Control group: placebo.

Treatment - Drugs

Placebo

Intervention group: curcumin (1500 mg/day)

Control group: placebo

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Documented sulfur mustard exposure and documented respiratory damage due to mustard intoxication. Exclusion: Participation in a concomitant trial; presence of life-threatening disorders; smoking and addiction; cardiovascular disease; lung cancer; pneumonia; acute bronchitis; development of severe drug-related adverse events; use of antioxidant supplements/drugs in the preceding three months; lungectomy and aggravation of symptoms during the course of study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvement of patients' quality of life. Timepoint: After four weeks of treatment. Method of measurement: Based on the st. George questionnaire.;Improvement of respiratory symptoms. Timepoint: After four weeks of treatment. Method of measurement: Based on the CAT questionnaire.	—

Secondary

Measure	Time frame
Changes in serum levels of tumor necrosis factor-alpha. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of transforming growth factor-beta. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels interleukin 6. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels interleukin 8. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of macrophage chemotactic protein-1. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of substance P. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of C-reactive protein. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of calcitonin gene-related peptide. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).	—

Measure

Time frame

Changes in serum levels of tumor necrosis factor-alpha. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of transforming growth factor-beta. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels interleukin 6. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels interleukin 8. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of macrophage chemotactic protein-1. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of substance P. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of C-reactive protein. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Changes in serum levels of calcitonin gene-related peptide. Timepoint: After four weeks of treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYunes Panahi

Chemical Injuries Research Center, Baqiyatallah university of Medical Sciences

yunespanahi@yahoo.com+98 218829260

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026